HLA-A and non-small cell lung carcinoma: Among NSCLC patients treated with nivolumab, those not expressing HLA-A*02 and alleles had inferior outcomes with progression-free survival (PFS) of 7.5 months, while HLA-A*-01 positive patients had the best outcome with a PFS of 22.6 months.